Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

(73)

Change in fair value

of warrant liability (0) 471 471

Other 2 2

Deemed dividend - (19,424) (19,424)

Preferred stock

accretion - (41) (41)

Summary:

Income (loss) before

income taxes: (8,338) 471 (41) (19,424) (757) (28,089)

Net income (loss): (8,338) 471 (41) (19,424) (757) (28,089)

Net income (loss)

per share - basic

and diluted: (11.59) 0.65 (0.06) (26.99) (1.05) (39.04)

Weighted average

number of shares

outstanding: 719,556 719,556


'/>"/>
SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire... that the Anti-infective Drugs Advisory Committee ...s voted 17 to 2 against the,approval of intraveno...t for,the treatment of patients with complicated ...uding those caused by methicillin-resistant Staphy...
(Date:11/20/2008)... LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ ... DSKA), announced today that it has submitted its,...r review under a Special,Protocol Assessment (SPA...tion,(FDA). , Subject to securing an agree...ngle, prospective, double-blind, placebo-controlle...
(Date:11/20/2008)... BOSTON, Nov. 20 PAREXEL...ading global biopharmaceutical services provider, ...ma, Peru to provide regulatory consulting and clin...he Peru office, PAREXEL now has locations througho...in America, which also include Argentina, Brazil, ...
(Date:11/19/2008)... THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstC...he Takeda Oncology Company, a subsidiary of,Taked...y announced that,enrollment in the Phase 3 MONET1...ion with paclitaxel and carboplatin for the first-...ncer (NSCLC) has been temporarily suspended,follo...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7High Blood Pressure May Heighten Effects of Alzheimers Disease 934 1High Blood Pressure May Heighten Effects of Alzheimers Disease 934 2Transporters may help delay diabetes related retinal damage 7116 1Transporters may help delay diabetes related retinal damage 7116 2Transporters may help delay diabetes related retinal damage 7116 3Nanotechnology and the media 3A The inside story 1364 1Nanotechnology and the media 3A The inside story 1364 2Promising Data ATIR Studies Presented by NIH Investigators 1980 1Promising Data ATIR Studies Presented by NIH Investigators 1980 2
(Date:11/22/2008)... Open enrollment is now happ...over expenses not covered by Medicare, and may als... consumers are now shopping online for instant quo...ort Collins, CO (PRWEB) November 21, 2008 -- MediG... for Medicare Supplement plans . Medicare Advant...
(Date:11/21/2008)...NGE COUNTY, Calif., Nov. 21 Album ...ting firm, launches a new program offering big bra...have taken the large, expensive ad agency process ...s with a very hands-on approach," says Matt Parker... 2002, combines experience and proven brand-buildi...
(Date:11/21/2008)...s, parents and schools need to work together to st...DAY, Nov. 21 (HealthDay News) -- Behavior that was...ized as bullying. , And as mounting research sh... victim, mental-health professionals, schools, par...ew ways to combat this threatening behavior. ,...
(Date:11/21/2008)... TALLAHASSEE, Fla. -- A Florida State University C...ang has discovered an important new layer of regul... to a greater understanding of the way cancer begi... sciences at the College of Medicine, said the fin... cancer and could lead to the design of new drugs ...
Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3
...growth of colon polyps to half, it doubles the ris...by two significant studies published in the Aug. 3...e opinions of Bruce M. Psaty, M.D., Ph.D., and Joh...iversity of Washington were also published along w...
... only reverses the arterial dysfunction caused by ...ame arteries compared to before the meal, accordin...dings, reported in the European Journal of Applied...us on the effect food has on the body after the me...
...reas preoperative brain could effectively alter th...pear in the September issue of Radiology, states t...uage areas of the brain with functional magnetic r...e surgeons in pinpointing the brain tumors more ef...
...as challenged the view of The Sterling Council, of...alarm service, which the// Scottish public service...minced words that the ruling is a target at the we...ruly a mockery of the free care provided for the e...
Other Medicine News:Health News:Celebrex- pros and cons 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: